- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2019-05
2021-05
2022-05
9
NCT03941457
Asclepius Technology Company Group (Suzhou) Co., Ltd.
Asclepius Technology Company Group (Suzhou) Co., Ltd.
INTERVENTIONAL
Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer
Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. ROBO1 is a potential target and spectacular paradigm in the treatment of solid tumors. This study is for evaluation of the safety and efficacy of ROBO1 CAR-NK cell immunotherapy for pancreatic cancer.
N/A
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2019-05-06 | N/A | 2019-05-06 |
2019-05-06 | N/A | 2019-05-08 |
2019-05-08 | N/A | 2019-05 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
Treatment
Allocation:
Na
Interventional Model:
Single Group
Masking:
None
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| EXPERIMENTAL: anti-tumor response of BiCAR-NK cells (ROBO1 CAR-NK cells) Patients with relapsed and refractory pancreatic cancer of ROBO1 expression will be treated with BiCAR-NK cells (ROBO1 CAR-NK cells). | BIOLOGICAL: BiCAR-NK cells (ROBO1 CAR-NK cells)
|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Occurrence of treatment related adverse events as assessed by CTCAE v4.03 | Defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment. | 1 year |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: Guangfu Li Phone Number: +86 13615181959 Email: lgf@atcgcell.com |
Study Contact Backup Name: Xianfeng Feng Phone Number: +86 15157190521 Email: fxf@atcgcell.com |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
